Article
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics.
The new microbiologica - 1 Oct 2015
Tontodonati Monica, Cento Valeria, Polilli Ennio, Colabattista Cecilia, Cascella Raffaella, Sciotti Mariapina, Di Giammartino Dante, Trave Francesca, Di Maio Velia Chiara, Monarca Roberto, Di Candilo Francesco, Prinapori Roberta, Rastrelli Elena, Vecchiet Jacopo, Ceccherini-Silberstein Francesca, Manzoli Lamberto, Giardina Emiliano, Perno Carlo Federico, Parruti Giustino
Abstract excerpt
When treating HCV patients with conventional dual therapy in the current context of rapidly evolving HCV therapy, outcome prediction is crucial and HCV kinetics, as early as 48 hours after the start of treatment, may play a major role. We aimed at clarifying the role of HCV very early kinetics. We consecutively enrolled mono-infected HCV patients at 7 treatment sites in Central Italy and evaluated the predictive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.